CONSIDER THE **SYNCHRONY HISTOLOGY** STUDY

NASH is a type of nonalcoholic fatty liver disease (NAFLD). The condition starts with a build-up of fat in the liver, damage to liver cells, and soreness, which eventually leads to scarring. Almost 80 million people have NAFLD in the United States, and about 1 in 5 of them will end up with NASH.

To reduce the risk of liver failure, the first advice doctors give their patients with NAFLD and NASH is to eat healthier foods and get more exercise. But these changes are not enough to help many people who have this form of liver disease.

The SYNCHRONY Histology study is testing an investigational drug called EFX to see whether it may help slow down or possibly reverse scarring of the liver in NASH.

Clinical trials encourage everyone with the disease (or that suspect they have the disease) to participate to advance treatment for everyone with NAFLD.

Learn More Today

For more information about this study, please visit AkeroSynchronyProgram.com/Histology or contact:

synchrony HISTOLOGY

AK-US-001-0105_Brochure_v1.0_03AUG2023

akero

HAVE YOU BEEN STRUGGLING TO **IMPROVE YOUR LIVER HEALTH?**

Find out more about SYNCHRONY Histology, a clinical trial of an investigational drug for nonalcoholic steatohepatitis, or NASH

synchrony HISTOLOGY

akero

About the SYNCHRONY Histology Study

The SYNCHRONY Histology study is a clinical trial to see what effect an investigational drug, EFX, has on scarring of the liver in NASH. All participants will need to have NASH shown in a liver biopsy (sample of liver tissue). The biopsy may be obtained previously (within 1 year), or during the screening process.

Participants will be randomly assigned (as if by the toss of a coin) to get either EFX 28 mg, EFX 50 mg, or placebo, which is a liquid that looks like EFX but has no active ingredients. Whichever group you are in, you will give yourself a shot once a week, along with taking your usual medications.

There is a 2 in 3 (66%) chance of getting EFX, but you will not be able to choose. Neither you nor the study team working with you will know whether you are getting EFX or placebo.

What to Expect

The SYNCHRONY Histology study lasts up to 112 weeks and includes:

- **Screening period:** 12 weeks
- **Treatment period:** 52 weeks
- **Long-term treatment period:** 44 weeks
- **Safety follow-up period:** 30 days

Participation involves about 24 clinic visits.

Who Can Join?

You may be able to take part in the SYNCHRONY Histology study if you:

- Are 18 to 75 years old
- Have had a liver biopsy that showed NASH or are willing to undergo a biopsy
- Have or ever had type 2 diabetes or 2 out of 4 signs of metabolic syndrome (overweight, have high cholesterol, blood pressure, and/or blood glucose)
- Have a body mass index (BMI) ≥25.0 kg/m²

There are other requirements. Please ask for details.

Why Take Part?

We cannot promise any direct benefit from taking part in the SYNCHRONY Histology study, but possible benefits may include:

- Access to the study drug, EFX
- Close care from a team of medical professionals at no cost
- Helping doctors learn more about NASH/NAFLD and fibrosis, which may help others in the future

About Clinical Studies

A clinical research study is careful research that is done before a study drug can be made available to the public. All clinical studies are reviewed by independent ethics groups (Institutional Review Board or Independent Ethics Committee) to review the plans for the study to protect the rights and welfare of those participating in studies

- Clinical studies follow strict rules to protect the rights, safety, well-being, and privacy of participants
- The results help government officials decide if a medication works, is safe, and should be available to patients
- Clinical trials are the only way to come up with new medical treatments to improve patient care

Taking part in the SYNCHRONY Histology study is up to you. If you choose to join, you can change your mind and leave at any time without giving a reason. If you decide not to take part, it will not affect your usual medical care now or in the future.

synchrony HISTOLOGY

akero